M. Martín

发表

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

M. Martín, R. Barakat, Miguel Martín, 2015, Clinical and Translational Oncology.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

A. Carrato, J. Albanell, B. Munárriz, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer

M. Martín, J. García-Saenz, E. Díaz-Rubio, 2008, Journal of chemotherapy.

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

M. Martín, J. García-Saenz, E. Díaz-Rubio, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

F. Rojo, J. Albanell, A. Lluch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy.

J. Garcia-conde, A. Lluch, M. Martín, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

A. Ruíz, A. Lluch, V. Guillem, 2014, British Journal of Cancer.

The severity and pattern of emesis following different cytotoxic agents.

M. Martín, Miguel Martín, M. Martín, 1996, Oncology.

Review: circulating tumor cells in the practice of breast cancer oncology

M. Martín, J. García-Saenz, F. Moreno, 2016, Clinical and Translational Oncology.

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

W. Eiermann, H. Rugo, Y. Im, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

P. Neven, B. Naume, I. Láng, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The natural course of emesis after carboplatin treatment.

J. Almenarez, E. Díaz-Rubio, M. Martín, 1990, Acta oncologica.

Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials

P. Neven, A. Bardia, L. Hart, 2019, Poster Session Abstracts.

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

M. Martín, M. Riesco-Martinez, P. García-Alfonso, 2010, British Journal of Cancer.

Current controversies in the management of early breast cancer

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

M. Martín, J. García-Saenz, J. A. Guerra Martínez, 2019, Clinical and Translational Oncology.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

M. Campone, A. Manikhas, L. Dirix, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study

M. Margelí, E. Alba, N. Ribelles, 2007 .

SEOM clinical guidelines in metastatic breast cancer 2015

M. Martín, S. Morales, I. Álvarez, 2015, Clinical and Translational Oncology.

Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.

I. Barneto, E. Díaz-Rubio, E. Aranda, 1990, European journal of cancer.

Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.

M. Namer, D. Dodwell, C. Unger, 2001, Clinical breast cancer.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

A. Tres, E. Alba, M. Martín, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant treatments for triple-negative breast cancer (TNBC).

G. von Minckwitz, M. Martín, G. Minckwitz, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

H. Sommer, M. Untch, P. Kellokumpu-Lehtinen, 2006, British Journal of Cancer.

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

C. Perou, Xiaping He, M. Cheang, 2011, Breast Cancer Research and Treatment.

Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.

J. García-Saenz, T. Caldés, A. Romero, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection

C. Perou, A. Pelayo, A. Prat, 2013, Clinical and Translational Oncology.

Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.

M. Martín, J. García-Saenz, T. Caldés, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

A. Lluch, E. Alba, M. Martín, 2018, Clinical and Translational Oncology.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

F. Saad, A. Stopeck, D. Yardley, 2016, European journal of cancer.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.

P. Fasching, P. Neven, S. Im, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum compounds in the treatment of advanced breast cancer.

Miguel Martín, M. Martín, M. Martín, 2001, Clinical breast cancer.

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

M. Campone, P. Fumoleau, H. Cortés-Funes, 2006, British Journal of Cancer.

Prednimustine-induced myoclonus--a report of three cases.

Á. Rodríguez-Lescure, J. López-Martín, E. Díaz-Rubio, 1994, Acta oncologica.

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology

M. Pollán, Miguel Martín, M. Seguí-Palmer, 2020, Clinical and Translational Oncology.

Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg

A. Leo, G. Jerusalem, M. Martín, 2012 .

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

J. Gralow, M. Martín, C. Zielinski, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in invasive lobular carcinoma of the breast: a multivariate analysis. A multicentre study after seventeen years of follow-up.

J. San Román, C. Fernández, E. Díaz Rubio, 1999, Annales chirurgiae et gynaecologiae.

Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer

A. Howell, J. Hainsworth, J. Mackey, 2005 .

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

P. Fasching, H. Rugo, K. Tamura, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

F. Rojo, J. Albanell, M. Martín, 2017, Clinical and Translational Oncology.

Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.

J. Garcia-conde, A. Lluch, Á. Rodríguez-Lescure, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.

M. Sanz-Casla, J. García-Saenz, E. Díaz-Rubio, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer

C. Perou, T. Nielsen, M. Cheang, 2012 .

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

J. Bergh, C. Sotiriou, B. Gusterson, 2012, Breast.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

J. Albanell, M. Campone, P. Fumoleau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

P. Neven, K. Gelmon, H. Rugo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.

J. Schneider, Á. Ruibal, M. Martín, 2000, Anticancer research.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

SEOM Clinical Guideline for bone metastases from solid tumours (2016)

M. Martín, M. A. Seguí, C. Grávalos, 2016, Clinical and Translational Oncology.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

C. Perou, K. Hoadley, A. Picornell, 2019, BMC Genomics.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

M. Buyse, L. Fallowfield, D. Cella, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.

A. Guerrero-Zotano, M. Koehler, M. Margelí, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

E. Winer, C. Hudis, W. Barry, 2019, European journal of cancer.

Phase II trial of UFT activity in pretreated breast cancer patients.

J. Garcia-conde, V. Guillem, C. Herranz, 1993, Japanese journal of clinical oncology.

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

P. Neven, V. Tjan-Heijnen, I. Láng, 2020, Clinical and Translational Oncology.

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

T. Conroy, G. Auclerc, D. Khayat, 1996, European journal of cancer.

SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups

M. Martín, C. Rodríguez, M. Martín, 2015, Clinical and Translational Oncology.

Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma

J. García-Saenz, E. Díaz-Rubio, A. Sánchez-Pernaute, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

D. Amadori, G. Sledge, S. Arbuck, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

J. Baselga, J. Albanell, R. Rosell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

J. Mackey, N. Robert, V. Valero, 2016 .

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

M. Press, A. Prat, G. Phillips, 2018 .

Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital

M. Martín, I. Márquez-Rodas, M. Lobo, 2016, Oncology.

Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study

Zhou Zhu, K. Gelmon, N. Harbeck, 2018 .

Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer

J. M. Jerez, J. Albanell, A. Prat, 2016 .

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

E. Felip, R. Andrés, F. Rivera, 2016, Clinical and Translational Oncology.

Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).

A. Lluch, A. Llombart-Cussac, E. Alba, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin: an active drug in metastatic breast cancer.

E. Adrover, E. Díaz-Rubio, M. Martín, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin in advanced breast cancer: preliminary results.

E. Díaz-Rubio, A. Casado, J. M. López Vega, 1991, Seminars in oncology.

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

S. Krishnamurthy, M. Aapro, M. Campone, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

A. Lluch, J. Zaluski, M. Martín, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).

H. Iwata, D. Finkelstein, P. Goss, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

S. Hurvitz, T. Usari, K. Lee, 2021, Annals of Oncology.

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment.

W. Eiermann, H. Rugo, I. C. Tudor, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.

M. Margelí, M. Martín, E. Carrasco, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

K. Gelmon, H. Rugo, R. Finn, 2016 .

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

L. Zelek, M. Namer, A. Lluch, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.

A. Lluch, B. Massuti, M. Martín, 1997, Seminars in oncology.

A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes

J. Godino, P. Pérez-Segura, T. Caldés, 2002, Journal of medical genetics.

Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC).

C. Perou, Xiaping He, M. Cheang, 2010 .

Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.

A. Abad, E. Díaz-Rubio, M. Martín, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain

A. Ruíz, L. Cerezo, M. Martín, 2014, Clinical and Translational Oncology.

Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.

J. Garcia-conde, A. Lluch, M. Martín, 1993, Cancer treatment reviews.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors.

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2018, Annals of Oncology.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

K. Gelmon, R. Finn, S. Im, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

A. Bardia, J. Spoerke, J. Giltnane, 2018 .

Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks

J. M. Jerez, A. Lluch, A. Llombart-Cussac, 2005, Breast Cancer Research and Treatment.

Prognostic Value of DNA Quantification in Early Epithelial Ovarian Carcinoma

E. Díaz-Rubio, J. Vidart, M. Martín, 2001, Obstetrics and gynecology.

Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study.

F. Baillet, J. Depondt, P. Géhanno, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.

J. Depondt, P. Géhanno, G. Lelièvre, 1993, Oncology.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

C. Perou, K. Hoadley, A. Picornell, 2019, BMC Genomics.

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial.

A. Ruíz, E. Alba, B. Munárriz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study.

A. Lluch, M. Martín, M. Ramos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

M. Press, M. Martín, E. Petru, 2018 .

A randomized study of CDDP and 5-FU as Neo-Adjuvant chemotherapy in head and neck cancer: an interim analysis

J. Mazeron, R. Peynègre, E. Malaurie, 1994 .

Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis.

N. Harbeck, C. Kaiser, A. Llombart-Cussac, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC).

M. Ramos, J. García-Saenz, M. Muñoz, 2009, Journal of Clinical Oncology.

Acute and anticipatory emesis in breast cancer patients

Á. Rodríguez-Lescure, J. Sanchez, E. Díaz-Rubio, 1996, Supportive Care in Cancer.

Abstract S4-06: Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer

M. Press, M. Martín, E. Petru, 2017 .

Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors.“The P

M. Koehler, M. Margelí, C. H. Bartlett, 2017 .

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

W. Eiermann, Y. Im, M. Martín, 2016 .

Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer

A. Manikhas, J. Cortes, V. Diéras, 2019, Poster Discussion Abstracts.

SEOM guidelines 2016: an update

A. Santaballa, M. Martín, 2016, Clinical and Translational Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study.

J. Mayordomo, I. Álvarez, A. Antón, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Jianming Xu, M. Press, G. Phillips, 2017 .

Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.

E. Díaz-Rubio, A. Casado, S. Dominguez, 1992, European journal of cancer.

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

J. Palacios, E. de Álava, X. Matías-Guiu, 2017, Clinical and Translational Oncology.

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

M. Martín, M. Ramos, Á. Rodríguez-Lescure, 2008 .

Ifosfamide encephalopathy and methylene-blue: a case report.

Y. Nieto, E. Díaz-Rubio, M. Martín, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis.

E. Díaz-Rubio, M. Martín, 1990, Annals of Oncology.

Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines.

E. Díaz-Rubio, A. Casado, I. García Carbonero, 1998, Oncology.

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

T. Whelan, S. Aparicio, K. Gelmon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC).

J. Forbes, V. Valero, W. Eiermann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study

M. Cebollero, I. Márquez-Rodas, J. G. García Sáenz, 2022, Annals of Oncology.

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

M. Martín, J. García-Saenz, J. C. de la Torre-Montero, 2018, Breast Cancer Research and Treatment.

P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

W. Eiermann, H. Rugo, M. Martín, 2015 .

High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT).

M. Martín, M. Martín, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.

J. Garcia-conde, A. Lluch, E. Díaz-Rubio, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Ifosfamide in advanced epidermoid head and neck cancer

J. Almenarez, E. Díaz-Rubio, A. Casado, 2004, Cancer Chemotherapy and Pharmacology.

Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

M. Martín, J. García-Saenz, J. C. de la Torre-Montero, 2018, Breast Cancer Research and Treatment.

Lethal Cardiac Toxicity after Cisplatin and 5‐Fluorouracil Chemotherapy: Report of a Case with Necropsy Study

J. Almenarez, E. Díaz-Rubio, M. Martín, 1989, American journal of clinical oncology.

Phase III study of gemcitabine plus vinorelbine (VG) versus vinorelbine (V) in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracyclines (A) and taxanes (T). Final results of GEICAM 2000-04 study.

E. Alba, L. Calvo, M. Muñoz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)

K. Gelmon, M. Gnant, A. Makris, 2013 .

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

A. Lluch, E. Alba, E. Carrasco, 2018, European journal of cancer.